Vertex Kidney Drug Trial Sparks 6.3% Gain, Boosts iShares Biotech ETF 8.7% Weight
Vertex’s Phase 3 RAINIER trial of povetacicept in IgA nephropathy achieved a 49.8% UPCR reduction versus placebo and 52% reduction from baseline at Week 36, with 85.1% hematuria resolution and 77.4% drop in serum Gd-IgA1. iShares Biotechnology ETF allocates 8.7% to Vertex.
1. Vertex RAINIER Trial Success
Vertex’s Phase 3 RAINIER trial of povetacicept in immunoglobulin A nephropathy met its primary endpoint, achieving a 52% reduction from baseline in urine protein-to-creatinine ratio (UPCR) at Week 36 and a 49.8% reduction versus placebo. Additionally, 85.1% of patients with baseline hematuria achieved resolution and serum galactose-deficient IgA1 levels fell by 77.4%, prompting an FDA rolling review.
2. Vertex Share Reaction
In premarket trading, Vertex shares surged 6.32% following the interim RAINIER data, extending gains above both the 20-day and 100-day simple moving averages. The move underscores investor confidence in the company’s kidney drug pipeline despite mixed longer-term technical momentum.
3. Impact on iShares Biotechnology ETF
iShares Biotechnology ETF holds 8.7% of its assets in Vertex, making the company one of its largest positions. Vertex’s stock jump could lift the ETF’s net asset value and spur inflows, given its significant weighting among top biotech names.
4. Next Steps and Outlook
Vertex plans to complete its full Biologics License Application submission for povetacicept by the end of March, seeking priority review under the voucher program and potential approval by year-end. Material revenue from the therapy in IgA nephropathy is not expected until 2027, pending pricing, reimbursement dynamics and formulary placements.